Sodium oxybate (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Sodium oxybate" in English language version.

refsWebsite

Global rank English rank

36nih.gov

4^th place

23doi.org

2^nd place

12web.archive.org

1^st place

5fda.gov

447^th place

338^th place

5semanticscholar.org

11^th place

8^th place

4nytimes.com

7^th place

3sec.gov

572^nd place

436^th place

2handle.net

102^nd place

76^th place

2books.google.com

3^rd place

2washingtonpost.com

34^th place

27^th place

2thepharmaletter.com

low place

2hsj.co.uk

low place

6,091^st place

1drugs.com

399^th place

333^rd place

1canada.ca

1,712^th place

1,063^rd place

1medicines.org.uk

3,823^rd place

2,387^th place

1who.int

195^th place

302^nd place

1agenziafarmaco.gov.it

low place

1dea.gov

8,191^st place

5,785^th place

1fiercepharmamarketing.com

low place

1justice.gov

918^th place

556^th place

1europeanreview.org

low place

1eurekaselect.com

low place

1zenodo.org

621^st place

380^th place

1cdc.gov

218^th place

212^th place

1samhsa.gov

low place

1streetinsider.com

low place

1usdoj.gov

2,755^th place

1,753^rd place

1ucsb.edu

1,115^th place

741^st place

1theguardian.com

12^th place

11^th place

1thefreelibrary.com

518^th place

331^st place

1investors.com

low place

6,516^th place

1hikma.com

low place

1medscape.com

719^th place

636^th place

1nice.org.uk

3,258^th place

2,666^th place

1ntag.nhs.uk

low place

1cato.org

4,789^th place

3,253^rd place

1nhs.uk

1,989^th place

1,528^th place

1europa.eu

68^th place

117^th place

agenziafarmaco.gov.it

farmaci.agenziafarmaco.gov.it

"Alcover: Riassunto delle Caratteristiche del Prodotto". Agenzia Italiana del Farmaco. March 31, 2017. Index page

books.google.com

Miller RL (2002). "GHB". The Encyclopedia of Addictive Drugs. Greenwood Publishing Group. pp. 182–185. ISBN 9780313318078.
Abadinsky H (2010). "GHB and GBL". Drug Use and Abuse: A Comprehensive Introduction (7th ed.). Cengage Learning. pp. 197–198. ISBN 9780495809913.

canada.ca

health-products.canada.ca

"Xyrem Product information". Health Canada. January 3, 2018. Retrieved February 16, 2025.

cato.org

Danzon PM (Spring 2000). "Making sense of drug prices" (PDF). Regulation. 23 (1): 56–63. Archived from the original (PDF) on October 11, 2012. Retrieved October 5, 2010.

cdc.gov

Centers for Disease Control (CDC) (November 1990). "Multistate outbreak of poisonings associated with illicit use of gamma hydroxy butyrate". MMWR. Morbidity and Mortality Weekly Report. 39 (47): 861–863. PMID 2122223.

dea.gov

"GHB Fact Sheet" (PDF). DEA. Archived from the original (PDF) on April 16, 2018. Retrieved April 16, 2018.

doi.org

Tay E, Lo WK, Murnion B (2022). "Current Insights on the Impact of Gamma-Hydroxybutyrate (GHB) Abuse". Substance Abuse and Rehabilitation. 13: 13–23. doi:10.2147/SAR.S315720. PMC 8843350. PMID 35173515.
Busardò FP, Jones AW (January 2015). "GHB pharmacology and toxicology: acute intoxication, concentrations in blood and urine in forensic cases and treatment of the withdrawal syndrome". Current Neuropharmacology. 13 (1): 47–70. doi:10.2174/1570159X13666141210215423. PMC 4462042. PMID 26074743.
Wang YG, Swick TJ, Carter LP, Thorpy MJ, Benowitz NL (August 2009). "Safety overview of postmarketing and clinical experience of sodium oxybate (Xyrem): abuse, misuse, dependence, and diversion". Journal of Clinical Sleep Medicine. 5 (4): 365–371. doi:10.5664/jcsm.27549. PMC 2725257. PMID 19968016.
Alshaikh MK, Tricco AC, Tashkandi M, Mamdani M, Straus SE, BaHammam AS (August 2012). "Sodium oxybate for narcolepsy with cataplexy: systematic review and meta-analysis". Journal of Clinical Sleep Medicine. 8 (4): 451–458. doi:10.5664/jcsm.2048. PMC 3407266. PMID 22893778.
Boscolo-Berto R, Viel G, Montagnese S, Raduazzo DI, Ferrara SD, Dauvilliers Y (October 2012). "Narcolepsy and effectiveness of gamma-hydroxybutyrate (GHB): a systematic review and meta-analysis of randomized controlled trials". Sleep Medicine Reviews. 16 (5): 431–443. doi:10.1016/j.smrv.2011.09.001. PMID 22055895.
Keating GM (January 2014). "Sodium oxybate: a review of its use in alcohol withdrawal syndrome and in the maintenance of abstinence in alcohol dependence". Clinical Drug Investigation. 34 (1): 63–80. doi:10.1007/s40261-013-0158-x. PMID 24307430. S2CID 2056246.
Mannucci C, Pichini S, Spagnolo EV, Calapai F, Gangemi S, Navarra M, et al. (2018). "Sodium Oxybate Therapy for Alcohol Withdrawal Syndrome and Keeping of Alcohol Abstinence". Current Drug Metabolism. 19 (13): 1056–1064. doi:10.2174/1389200219666171207122227. PMID 29219048. S2CID 2166038.
Addolorato G, Lesch OM, Maremmani I, Walter H, Nava F, Raffaillac Q, et al. (February 2020). "Post-marketing and clinical safety experience with sodium oxybate for the treatment of alcohol withdrawal syndrome and maintenance of abstinence in alcohol-dependent subjects". Expert Opinion on Drug Safety. 19 (2): 159–166. doi:10.1080/14740338.2020.1709821. PMID 31876433. S2CID 209482660.
van den Brink W, Addolorato G, Aubin HJ, Benyamina A, Caputo F, Dematteis M, et al. (July 2018). "Efficacy and safety of sodium oxybate in alcohol-dependent patients with a very high drinking risk level". Addiction Biology. 23 (4): 969–986. doi:10.1111/adb.12645. PMID 30043457. S2CID 51716274.
Swick T (2011). "Sodium Oxybate: A Potential New Pharmacological Option for the Treatment of Fibromyalgia Syndrome". Ther Adv Musculoskelet Dis. 3 (4): 167–178. doi:10.1177/1759720X11411599. PMC 3382678. PMID 29219048.
Galloway GP, Frederick SL, Staggers FE, Gonzales M, Stalcup SA, Smith DE (January 1997). "Gamma-hydroxybutyrate: an emerging drug of abuse that causes physical dependence". Addiction. 92 (1): 89–96. doi:10.1111/j.1360-0443.1997.tb03640.x. PMID 9060200.
Wedin GP, Hornfeldt CS, Ylitalo LM (January 2006). "The clinical development of gamma-hydroxybutyrate (GHB)". Current Drug Safety. 1 (1): 99–106. doi:10.2174/157488606775252647. PMID 18690919.
Carter LP, Pardi D, Gorsline J, Griffiths RR (September 2009). "Illicit gamma-hydroxybutyrate (GHB) and pharmaceutical sodium oxybate (Xyrem): differences in characteristics and misuse". Drug and Alcohol Dependence. 104 (1–2): 1–10. doi:10.1016/j.drugalcdep.2009.04.012. PMC 2713368. PMID 19493637.
Wise MS, Arand DL, Auger RR, Brooks SN, Watson NF (December 2007). "Treatment of narcolepsy and other hypersomnias of central origin". Sleep. 30 (12): 1712–1727. doi:10.1093/sleep/30.12.1712. PMC 2276130. PMID 18246981.
Mamelak M. "Sleep, Narcolepsy, and Sodium Oxybate". Current Neuropharmacology. 20 (2): 272–291. doi:10.2174/1570159X19666210407151227. PMC 9413790.
Robinson DM, Keating GM (2007). "Sodium oxybate: a review of its use in the management of narcolepsy". CNS Drugs. 21 (4): 337–354. doi:10.2165/00023210-200721040-00007. PMID 17381187.
Felmlee MA, Morse BL, Morris ME (January 2021). "γ-Hydroxybutyric Acid: Pharmacokinetics, Pharmacodynamics, and Toxicology". The AAPS Journal. 23 (1): 22. doi:10.1208/s12248-020-00543-z. PMC 8098080. PMID 33417072.
Taxon ES, Halbers LP, Parsons SM (May 2020). "Kinetics aspects of Gamma-hydroxybutyrate dehydrogenase". Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics. 1868 (5): 140376. doi:10.1016/j.bbapap.2020.140376. PMID 31981617.
Kamal RM, van Noorden MS, Franzek E, Dijkstra BA, Loonen AJ, De Jong CA (March 2016). "The Neurobiological Mechanisms of Gamma-Hydroxybutyrate Dependence and Withdrawal and Their Clinical Relevance: A Review". Neuropsychobiology. 73 (2): 65–80. doi:10.1159/000443173. hdl:2066/158441. PMID 27003176.
Saytzeff A (1874). "Über die Reduction des Succinylchlorids". Liebigs Annalen der Chemie (in German). 171 (2): 258–290. doi:10.1002/jlac.18741710216.
Dyer JE (July 1991). "gamma-Hydroxybutyrate: a health-food product producing coma and seizurelike activity". The American Journal of Emergency Medicine. 9 (4): 321–324. doi:10.1016/0735-6757(91)90050-T. PMID 2054002.
Mason PE, Kerns WP (July 2002). "Gamma hydroxybutyric acid (GHB) intoxication". Academic Emergency Medicine. 9 (7): 730–739. doi:10.1197/aemj.9.7.730. PMID 12093716.
de Biase S, Nilo A, Gigli GL, Valente M (August 2017). "Investigational therapies for the treatment of narcolepsy". Expert Opinion on Investigational Drugs. 26 (8): 953–963. doi:10.1080/13543784.2017.1356819. PMID 28726523. S2CID 25638377.

drugs.com

"International brands for Sodium Oxybate -". Drugs.com. Retrieved April 16, 2018.

eurekaselect.com

Mamelak M. "Sleep, Narcolepsy, and Sodium Oxybate". Current Neuropharmacology. 20 (2): 272–291. doi:10.2174/1570159X19666210407151227. PMC 9413790.

europa.eu

ema.europa.eu

"Sodium oxybate: CHMP Scientific Discussion" (PDF). EMA. August 9, 2006. Archived from the original (PDF) on March 18, 2018. Retrieved April 16, 2018. Linked from EMA index page for EMEA 000593 Archived June 20, 2018, at the Wayback Machine

europeanreview.org

Busardò FP, Kyriakou C, Napoletano S, Marinelli E, Zaami S (December 2015). "Clinical applications of sodium oxybate (GHB): from narcolepsy to alcohol withdrawal syndrome" (PDF). European Review for Medical and Pharmacological Sciences. 19 (23): 4654–4663. PMID 26698265.

fda.gov

"Xyrem (sodium oxybate) Information". Center for Drug Evaluation and Research. U.S. Food and Drug Administration. January 25, 2017.
"Transcript: FDA Peripheral and Central Nervous System Drugs Advisory Committee Meeting". FDA. June 6, 2001. Archived from the original on August 6, 2001.
"FDA Warning Letter, Jazz Pharmaceuticals, Inc 10/11/11". Food and Drug Administration. Archived from the original on October 20, 2011.
"2013 - Jazz Pharmaceuticals, Inc.- Close Out Letter". FDA. August 2, 2013. Archived from the original on November 3, 2014.
"Press release: FDA approves a generic of Xyrem with a REMS Program". FDA Center for Drug Evaluation and Research. January 17, 2017. Archived from the original on January 20, 2017.

fiercepharmamarketing.com

Staton T (May 7, 2014). "10 big brands keep pumping out big bucks, with a little help from price hikes". Fierce Pharma. Retrieved November 13, 2015.

handle.net

hdl.handle.net

van den Brink W, Goudriaan A (May 11, 2023). Sodium oxybate for the treatment of alcohol dependence. University of Amsterdam. hdl:11245.1/ad0b0a9e-e28c-432d-81a9-ccdf39b190f8. ISBN 9789464730739. Retrieved August 11, 2023.
Kamal RM, van Noorden MS, Franzek E, Dijkstra BA, Loonen AJ, De Jong CA (March 2016). "The Neurobiological Mechanisms of Gamma-Hydroxybutyrate Dependence and Withdrawal and Their Clinical Relevance: A Review". Neuropsychobiology. 73 (2): 65–80. doi:10.1159/000443173. hdl:2066/158441. PMID 27003176.

hikma.com

"Hikma launches authorized generic of Xyrem (sodium oxybate) in the US". Hikma. Archived from the original on February 3, 2023. Retrieved February 3, 2023.

hsj.co.uk

"DH funds private prescriptions for drug denied to NHS patients". Health Service Journal. July 20, 2015. Retrieved July 20, 2015.
"Judge criticises NHS England for 'totally irrational' drug decision". Health Service Journal. May 4, 2016. Retrieved May 4, 2016.

investors.com

"This Rival Might Swipe 20% Of Jazz's Sleep Business, But Stock Perks Up | Investor's Business Daily". Investor's Business Daily. April 6, 2017.

justice.gov

"Press release: US Attorney's Office - Eastern District of New York". US Department of Justice. July 13, 2007.

medicines.org.uk

"UK label Summary of Product Characteristics". Electronic Medicines Compendium. September 8, 2015. Retrieved April 14, 2018.

medscape.com

Brooks M. "FDA OKs Once-Nightly Sodium Oxybate for Narcolepsy". Medscape. Retrieved July 14, 2023.

nhs.uk

"Narcolepsy". NHS Choices. May 29, 2016. Retrieved April 14, 2018.

nice.org.uk

"Narcolepsy with or without cataplexy in adults: pitolisant | Guidance and guidelines: Other Treatments". NICE. March 2017. Retrieved April 14, 2018.

nih.gov

pubmed.ncbi.nlm.nih.gov

Tay E, Lo WK, Murnion B (2022). "Current Insights on the Impact of Gamma-Hydroxybutyrate (GHB) Abuse". Substance Abuse and Rehabilitation. 13: 13–23. doi:10.2147/SAR.S315720. PMC 8843350. PMID 35173515.
Busardò FP, Jones AW (January 2015). "GHB pharmacology and toxicology: acute intoxication, concentrations in blood and urine in forensic cases and treatment of the withdrawal syndrome". Current Neuropharmacology. 13 (1): 47–70. doi:10.2174/1570159X13666141210215423. PMC 4462042. PMID 26074743.
Wang YG, Swick TJ, Carter LP, Thorpy MJ, Benowitz NL (August 2009). "Safety overview of postmarketing and clinical experience of sodium oxybate (Xyrem): abuse, misuse, dependence, and diversion". Journal of Clinical Sleep Medicine. 5 (4): 365–371. doi:10.5664/jcsm.27549. PMC 2725257. PMID 19968016.
Alshaikh MK, Tricco AC, Tashkandi M, Mamdani M, Straus SE, BaHammam AS (August 2012). "Sodium oxybate for narcolepsy with cataplexy: systematic review and meta-analysis". Journal of Clinical Sleep Medicine. 8 (4): 451–458. doi:10.5664/jcsm.2048. PMC 3407266. PMID 22893778.
Boscolo-Berto R, Viel G, Montagnese S, Raduazzo DI, Ferrara SD, Dauvilliers Y (October 2012). "Narcolepsy and effectiveness of gamma-hydroxybutyrate (GHB): a systematic review and meta-analysis of randomized controlled trials". Sleep Medicine Reviews. 16 (5): 431–443. doi:10.1016/j.smrv.2011.09.001. PMID 22055895.
Keating GM (January 2014). "Sodium oxybate: a review of its use in alcohol withdrawal syndrome and in the maintenance of abstinence in alcohol dependence". Clinical Drug Investigation. 34 (1): 63–80. doi:10.1007/s40261-013-0158-x. PMID 24307430. S2CID 2056246.
Busardò FP, Kyriakou C, Napoletano S, Marinelli E, Zaami S (December 2015). "Clinical applications of sodium oxybate (GHB): from narcolepsy to alcohol withdrawal syndrome" (PDF). European Review for Medical and Pharmacological Sciences. 19 (23): 4654–4663. PMID 26698265.
Mannucci C, Pichini S, Spagnolo EV, Calapai F, Gangemi S, Navarra M, et al. (2018). "Sodium Oxybate Therapy for Alcohol Withdrawal Syndrome and Keeping of Alcohol Abstinence". Current Drug Metabolism. 19 (13): 1056–1064. doi:10.2174/1389200219666171207122227. PMID 29219048. S2CID 2166038.
Addolorato G, Lesch OM, Maremmani I, Walter H, Nava F, Raffaillac Q, et al. (February 2020). "Post-marketing and clinical safety experience with sodium oxybate for the treatment of alcohol withdrawal syndrome and maintenance of abstinence in alcohol-dependent subjects". Expert Opinion on Drug Safety. 19 (2): 159–166. doi:10.1080/14740338.2020.1709821. PMID 31876433. S2CID 209482660.
van den Brink W, Addolorato G, Aubin HJ, Benyamina A, Caputo F, Dematteis M, et al. (July 2018). "Efficacy and safety of sodium oxybate in alcohol-dependent patients with a very high drinking risk level". Addiction Biology. 23 (4): 969–986. doi:10.1111/adb.12645. PMID 30043457. S2CID 51716274.
Swick T (2011). "Sodium Oxybate: A Potential New Pharmacological Option for the Treatment of Fibromyalgia Syndrome". Ther Adv Musculoskelet Dis. 3 (4): 167–178. doi:10.1177/1759720X11411599. PMC 3382678. PMID 29219048.
Galloway GP, Frederick SL, Staggers FE, Gonzales M, Stalcup SA, Smith DE (January 1997). "Gamma-hydroxybutyrate: an emerging drug of abuse that causes physical dependence". Addiction. 92 (1): 89–96. doi:10.1111/j.1360-0443.1997.tb03640.x. PMID 9060200.
Wedin GP, Hornfeldt CS, Ylitalo LM (January 2006). "The clinical development of gamma-hydroxybutyrate (GHB)". Current Drug Safety. 1 (1): 99–106. doi:10.2174/157488606775252647. PMID 18690919.
Carter LP, Pardi D, Gorsline J, Griffiths RR (September 2009). "Illicit gamma-hydroxybutyrate (GHB) and pharmaceutical sodium oxybate (Xyrem): differences in characteristics and misuse". Drug and Alcohol Dependence. 104 (1–2): 1–10. doi:10.1016/j.drugalcdep.2009.04.012. PMC 2713368. PMID 19493637.
Wise MS, Arand DL, Auger RR, Brooks SN, Watson NF (December 2007). "Treatment of narcolepsy and other hypersomnias of central origin". Sleep. 30 (12): 1712–1727. doi:10.1093/sleep/30.12.1712. PMC 2276130. PMID 18246981.
Robinson DM, Keating GM (2007). "Sodium oxybate: a review of its use in the management of narcolepsy". CNS Drugs. 21 (4): 337–354. doi:10.2165/00023210-200721040-00007. PMID 17381187.
Felmlee MA, Morse BL, Morris ME (January 2021). "γ-Hydroxybutyric Acid: Pharmacokinetics, Pharmacodynamics, and Toxicology". The AAPS Journal. 23 (1): 22. doi:10.1208/s12248-020-00543-z. PMC 8098080. PMID 33417072.
Taxon ES, Halbers LP, Parsons SM (May 2020). "Kinetics aspects of Gamma-hydroxybutyrate dehydrogenase". Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics. 1868 (5): 140376. doi:10.1016/j.bbapap.2020.140376. PMID 31981617.
Kamal RM, van Noorden MS, Franzek E, Dijkstra BA, Loonen AJ, De Jong CA (March 2016). "The Neurobiological Mechanisms of Gamma-Hydroxybutyrate Dependence and Withdrawal and Their Clinical Relevance: A Review". Neuropsychobiology. 73 (2): 65–80. doi:10.1159/000443173. hdl:2066/158441. PMID 27003176.
Laborit H, Jouany JM, Gerard J, Fabiani F (October 1960). "[Generalities concerning the experimental study and clinical use of gamma hydroxybutyrate of Na]". Agressologie (in French). 1: 397–406. PMID 13758011.
Centers for Disease Control (CDC) (November 1990). "Multistate outbreak of poisonings associated with illicit use of gamma hydroxy butyrate". MMWR. Morbidity and Mortality Weekly Report. 39 (47): 861–863. PMID 2122223.
Dyer JE (July 1991). "gamma-Hydroxybutyrate: a health-food product producing coma and seizurelike activity". The American Journal of Emergency Medicine. 9 (4): 321–324. doi:10.1016/0735-6757(91)90050-T. PMID 2054002.
Mason PE, Kerns WP (July 2002). "Gamma hydroxybutyric acid (GHB) intoxication". Academic Emergency Medicine. 9 (7): 730–739. doi:10.1197/aemj.9.7.730. PMID 12093716.
de Biase S, Nilo A, Gigli GL, Valente M (August 2017). "Investigational therapies for the treatment of narcolepsy". Expert Opinion on Investigational Drugs. 26 (8): 953–963. doi:10.1080/13543784.2017.1356819. PMID 28726523. S2CID 25638377.

ncbi.nlm.nih.gov

Tay E, Lo WK, Murnion B (2022). "Current Insights on the Impact of Gamma-Hydroxybutyrate (GHB) Abuse". Substance Abuse and Rehabilitation. 13: 13–23. doi:10.2147/SAR.S315720. PMC 8843350. PMID 35173515.
Busardò FP, Jones AW (January 2015). "GHB pharmacology and toxicology: acute intoxication, concentrations in blood and urine in forensic cases and treatment of the withdrawal syndrome". Current Neuropharmacology. 13 (1): 47–70. doi:10.2174/1570159X13666141210215423. PMC 4462042. PMID 26074743.
Wang YG, Swick TJ, Carter LP, Thorpy MJ, Benowitz NL (August 2009). "Safety overview of postmarketing and clinical experience of sodium oxybate (Xyrem): abuse, misuse, dependence, and diversion". Journal of Clinical Sleep Medicine. 5 (4): 365–371. doi:10.5664/jcsm.27549. PMC 2725257. PMID 19968016.
Alshaikh MK, Tricco AC, Tashkandi M, Mamdani M, Straus SE, BaHammam AS (August 2012). "Sodium oxybate for narcolepsy with cataplexy: systematic review and meta-analysis". Journal of Clinical Sleep Medicine. 8 (4): 451–458. doi:10.5664/jcsm.2048. PMC 3407266. PMID 22893778.
Swick T (2011). "Sodium Oxybate: A Potential New Pharmacological Option for the Treatment of Fibromyalgia Syndrome". Ther Adv Musculoskelet Dis. 3 (4): 167–178. doi:10.1177/1759720X11411599. PMC 3382678. PMID 29219048.
Carter LP, Pardi D, Gorsline J, Griffiths RR (September 2009). "Illicit gamma-hydroxybutyrate (GHB) and pharmaceutical sodium oxybate (Xyrem): differences in characteristics and misuse". Drug and Alcohol Dependence. 104 (1–2): 1–10. doi:10.1016/j.drugalcdep.2009.04.012. PMC 2713368. PMID 19493637.
Wise MS, Arand DL, Auger RR, Brooks SN, Watson NF (December 2007). "Treatment of narcolepsy and other hypersomnias of central origin". Sleep. 30 (12): 1712–1727. doi:10.1093/sleep/30.12.1712. PMC 2276130. PMID 18246981.
Mamelak M. "Sleep, Narcolepsy, and Sodium Oxybate". Current Neuropharmacology. 20 (2): 272–291. doi:10.2174/1570159X19666210407151227. PMC 9413790.
Felmlee MA, Morse BL, Morris ME (January 2021). "γ-Hydroxybutyric Acid: Pharmacokinetics, Pharmacodynamics, and Toxicology". The AAPS Journal. 23 (1): 22. doi:10.1208/s12248-020-00543-z. PMC 8098080. PMID 33417072.
Institute of Medicine, National Research Council (US) Committee on the Framework for Evaluating the Safety of Dietary Supplements (2002). "Appendix D: Table of Food and Drug Administration Actions on Dietary Supplements". Proposed Framework for Evaluating the Safety of Dietary Supplements: For Comment. National Academies Press (US).

dailymed.nlm.nih.gov

"Xyrem- sodium oxybate solution". DailyMed. Retrieved November 14, 2020.
"Lumryz- sodium oxybate for suspension, extended release". DailyMed. June 7, 2023. Retrieved March 23, 2024.

ntag.nhs.uk

Kane N (May 2017). "Sodium oxybate for the treatment of narcolepsy with cataplexy in adults" (PDF). NHS Regional Drug & Therapeutics Centre (Newcastle). Archived from the original (PDF) on October 21, 2020. Retrieved April 14, 2018.

nytimes.com

Berenson A (July 22, 2006). "Indictment of Doctor Tests Drug Marketing Rules". The New York Times.
Berenson A (July 14, 2007). "Maker of Narcolepsy Drug Pleads Guilty in U.S. Case". The New York Times.
"FDA Says No to Jazz Pharma Fibromyalgia Drug". The New York Times. Associated Press. October 12, 2010. Retrieved October 12, 2010.^{[dead link]}

opinionator.blogs.nytimes.com

Rattner S (June 30, 2013). "An Orphan Jackpot". The New York Times.

samhsa.gov

store.samhsa.gov

"GHB: A Club Drug To Watch" (PDF). Substance Abuse Treatment Advisory. 2 (1). November 2002. Archived from the original (PDF) on August 1, 2017. Retrieved April 16, 2018.

sec.gov

"Form S-1/A EX-10.41 Amended and Restated Xyrem License and Distribution Agreement". www.sec.gov. Jazz Pharmaceuticals vis SEC Edgar. March 27, 2007. Form S-1/A Index page
"10-K For the fiscal year ended December 31, 2017". Jazz via SEC Edgar. Retrieved April 16, 2018.
"8-K". www.sec.gov. Jazz via SEC Edgar. April 5, 2017.

semanticscholar.org

api.semanticscholar.org

Keating GM (January 2014). "Sodium oxybate: a review of its use in alcohol withdrawal syndrome and in the maintenance of abstinence in alcohol dependence". Clinical Drug Investigation. 34 (1): 63–80. doi:10.1007/s40261-013-0158-x. PMID 24307430. S2CID 2056246.
Mannucci C, Pichini S, Spagnolo EV, Calapai F, Gangemi S, Navarra M, et al. (2018). "Sodium Oxybate Therapy for Alcohol Withdrawal Syndrome and Keeping of Alcohol Abstinence". Current Drug Metabolism. 19 (13): 1056–1064. doi:10.2174/1389200219666171207122227. PMID 29219048. S2CID 2166038.
Addolorato G, Lesch OM, Maremmani I, Walter H, Nava F, Raffaillac Q, et al. (February 2020). "Post-marketing and clinical safety experience with sodium oxybate for the treatment of alcohol withdrawal syndrome and maintenance of abstinence in alcohol-dependent subjects". Expert Opinion on Drug Safety. 19 (2): 159–166. doi:10.1080/14740338.2020.1709821. PMID 31876433. S2CID 209482660.
van den Brink W, Addolorato G, Aubin HJ, Benyamina A, Caputo F, Dematteis M, et al. (July 2018). "Efficacy and safety of sodium oxybate in alcohol-dependent patients with a very high drinking risk level". Addiction Biology. 23 (4): 969–986. doi:10.1111/adb.12645. PMID 30043457. S2CID 51716274.
de Biase S, Nilo A, Gigli GL, Valente M (August 2017). "Investigational therapies for the treatment of narcolepsy". Expert Opinion on Investigational Drugs. 26 (8): 953–963. doi:10.1080/13543784.2017.1356819. PMID 28726523. S2CID 25638377.

streetinsider.com

"Jazz Pharma (JAZZ) Announces that Lonza has Terminated Their Sodium Oxybate Supply Agreement". Street Insider. March 25, 2010.

thefreelibrary.com

"Press release: Valeant Pharmaceuticals Signs Licensing Agreement for Canadian Rights to (C)Xyrem(R) (Sodium Oxybate) from Jazz Pharmaceuticals. - Free Online Library". Valeant via Business Wire. January 12, 2007. Archived from the original on June 18, 2018. Retrieved April 16, 2018.

theguardian.com

"Celltech sold to Belgian firm in £1.5bn deal". the Guardian. May 18, 2004.

thepharmaletter.com

"Celltech acquires rights to Xyrem from Orphan Medical - Pharmaceutical". The Pharma Letter. November 3, 2003.
"Jazz completes Orphan Medical buy - Pharmaceutical industry news". The Pharma Letter. July 4, 2005.

ucsb.edu

presidency.ucsb.edu

"William J. Clinton: Statement on Signing the Hillory J. Farias and Samantha Reid Date-Rape Drug Prohibition Act of 2000". February 18, 2000.

usdoj.gov

deadiversion.usdoj.gov

"2000 - Addition of Gamma-Hydroxybutyric Acid to Schedule I". US Department of Justice via the Federal Register. March 13, 2000. Archived from the original on May 1, 2021. Retrieved April 16, 2018.

washingtonpost.com

"FDA Approves 'Date-Rape' Drug to Treat Sleep Disorder". The Washington Post. July 18, 2002. Retrieved June 23, 2018.
"FDA Approves 'Date-Rape' Drug to Treat Sleep Disorder". Washington Post. July 18, 2002.

web.archive.org

"GHB Fact Sheet" (PDF). DEA. Archived from the original (PDF) on April 16, 2018. Retrieved April 16, 2018.
"GHB: A Club Drug To Watch" (PDF). Substance Abuse Treatment Advisory. 2 (1). November 2002. Archived from the original (PDF) on August 1, 2017. Retrieved April 16, 2018.
"Transcript: FDA Peripheral and Central Nervous System Drugs Advisory Committee Meeting". FDA. June 6, 2001. Archived from the original on August 6, 2001.
"2000 - Addition of Gamma-Hydroxybutyric Acid to Schedule I". US Department of Justice via the Federal Register. March 13, 2000. Archived from the original on May 1, 2021. Retrieved April 16, 2018.
"Press release: Valeant Pharmaceuticals Signs Licensing Agreement for Canadian Rights to (C)Xyrem(R) (Sodium Oxybate) from Jazz Pharmaceuticals. - Free Online Library". Valeant via Business Wire. January 12, 2007. Archived from the original on June 18, 2018. Retrieved April 16, 2018.
"FDA Warning Letter, Jazz Pharmaceuticals, Inc 10/11/11". Food and Drug Administration. Archived from the original on October 20, 2011.
"2013 - Jazz Pharmaceuticals, Inc.- Close Out Letter". FDA. August 2, 2013. Archived from the original on November 3, 2014.
"Press release: FDA approves a generic of Xyrem with a REMS Program". FDA Center for Drug Evaluation and Research. January 17, 2017. Archived from the original on January 20, 2017.
"Hikma launches authorized generic of Xyrem (sodium oxybate) in the US". Hikma. Archived from the original on February 3, 2023. Retrieved February 3, 2023.
Kane N (May 2017). "Sodium oxybate for the treatment of narcolepsy with cataplexy in adults" (PDF). NHS Regional Drug & Therapeutics Centre (Newcastle). Archived from the original (PDF) on October 21, 2020. Retrieved April 14, 2018.
Danzon PM (Spring 2000). "Making sense of drug prices" (PDF). Regulation. 23 (1): 56–63. Archived from the original (PDF) on October 11, 2012. Retrieved October 5, 2010.
"Sodium oxybate: CHMP Scientific Discussion" (PDF). EMA. August 9, 2006. Archived from the original (PDF) on March 18, 2018. Retrieved April 16, 2018. Linked from EMA index page for EMEA 000593 Archived June 20, 2018, at the Wayback Machine

who.int

"Critical review of gamma-hydroxybutyric acid (GHB)" (PDF). 2012.

zenodo.org

Saytzeff A (1874). "Über die Reduction des Succinylchlorids". Liebigs Annalen der Chemie (in German). 171 (2): 258–290. doi:10.1002/jlac.18741710216.